.
.
.: "arise: a phase 3 randomized trial of erenumab for episodic migraine."
.
.
.despite neutral imaging results, adalimumab did improve other key markers of inflammation in the blood including glyca, crp, tnf, and il-6.
.
lawmakers should revisit that idea when lepage is no longer in office next year.
.
.